GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elekta AB (OTCPK:EKTAY) » Definitions » Growth Rank

EKTAY (Elekta AB) Growth Rank : 6 (As of Mar. 31, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Elekta AB Growth Rank?

Elekta AB has the Growth Rank of 6.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Elekta AB's Growth Rank

For the Medical Devices subindustry, Elekta AB's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elekta AB's Growth Rank Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elekta AB's Growth Rank distribution charts can be found below:

* The bar in red indicates where Elekta AB's Growth Rank falls into.


;
;

Elekta AB Growth Rank Related Terms

Thank you for viewing the detailed overview of Elekta AB's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Elekta AB Business Description

Address
Kungstensgatan 18, Box 7593, Stockholm, SWE, SE-103 93
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 30%; Europe, the Middle East, and Africa accounting for 36%; and the Asia-Pacific contributing the remainder.

Elekta AB Headlines

From GuruFocus

Q4 2024 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 06-06-2024

Q4 2020 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2020 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2020 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2023 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q3 2020 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 02-13-2024

Elekta AB (publ) Capital Markets Day Transcript

By GuruFocus Research 02-13-2024

Q1 2025 Elekta AB (publ) Earnings Call Transcript

By GuruFocus Research 08-29-2024